Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: J Anal Toxicol. 2008 Oct;32(8):562–569. doi: 10.1093/jat/32.8.562

Table 2.

Urine cannabinoid data separated into three groups (0–50, 51–150 and >150 ng/mg) based on creatinine-normalized THCCOOH concentration in the first urine specimen at admission. Urine specimens were collected from cannabis users under continuous medical surveillance during cannabis abstinence for up to 30 days.

Subject THCCOOH/Creatinine in 1st Specimen (ng/mg) Time of 1st Negative Specimen (Days) Time of Last Positive Specimen (Days) Length of Observation (Days) # Urine Specimens Days Between 1st Negative & Last Positive Specimen # Specimens Between 1st Negative & Last Positive Urine Specimen CMAX (ng/mg) Between 1st Negative & Last Positive Specimen
0 to 50 ng/mg
A 47.3 1.7 4.3 4.8 47 4 31 32.4
B 30.1 0.3 1.5 6.9 71 2 14 15.7
C 34.6 1.6 3.8 4.4 30 3 17 16.5
E 9.8 0.0 2.2 5.1 26 3 10 9.8
H 46.8 1.4 1.2 2.8 18 1 0 ----2
L 27.8 0.3 0.0 29.9 109 1 0 ----2
AA 11.6 0.0 0.7 5.8 43 1 3 25.5
BB 1.8 0.0 ----1 2.9 19 ----1 ----1 ----1
DD 0.0 0.0 ----1 9.5 60 ----1 ----1 ----1
EE 40.4 1.4 3.3 16.3 73 3 9 42.1
GG 15.7 0.3 2.4 11.8 103 3 16 14.3
LL 24.8 0.1 21.8 21.8 87 22 86 30.2
MM 32.1 0.0 ----1 0.6 3 ----1 ----1 ----1
OO 29.5 1.2 5.6 5.7 37 5 30 27.0
RR 34.4 0.9 3.8 3.8 31 4 24 24.7
TT 15.5 0.0 ----1 1.7 15 ----1 ----1 ----1
ZZ 43.4 2.2 8.6 29.5 181 7 34 22.0
DDD 5.1 0.0 ----1 20.6 211 ----1 ----1 ----1
FFF 0.0 0.0 ----1 12.0 7 ----1 ----1 ----1
Mean ±SD 23.7± 15.9 0.6 ± 0.8 4.6 ± 5.6 10.3 ± 9.1 61.6 ± 56.8 4.5± 5.5 21.1 ± 22.6 23.6 ± 9.3
51 to 150 ng/mg
D 133.5 0.5 4.3 4.5 59 5 49 79.0
F 101.0 1.0 3.1 2.2 18 3 27 132.2
G 70.2 ----3 1.8 1.8 11 ----3 ----3 ----3
J 74.6 1.3 11.6 26.3 204 11 89 44.1
K 120.8 7.9 8.3 9.6 55 2 4 8.4
N 90.6 0.9 3.3 5.8 66 4 18 56.7
R 142.2 7.8 10.1 20.8 94 4 11 15.6
S 96.0 2.4 3.7 20.4 117 2 8 11.5
V 62.6 2.9 8.9 22.4 94 7 22 26.4
W 78.9 2.8 2.6 29.0 166 1 0 ----2
Y 83.7 6.7 16.0 29.2 109 11 37 112.7
CC 114.9 1.2 3.8 13.5 129 3 25 55.8
FF 61.9 2.2 25.3 25.7 194 24 164 38.8
HH 101.4 ----3 11.0 11.0 7 ----3 ----3 ----3
JJ 96.1 ----3 11.0 11.0 8 ----3 ----3 ----3
NN 120.7 3.7 12.1 18.6 164 10 77 71.6
QQ 110.0 1.2 10.7 24.6 174 10 78 83.0
WW 110.2 8.3 20.9 30.4 111 13 42 19.9
XX 92.3 0.0 17.0 27.9 264 17 139 55.9
CCC 71.0 1.7 5.0 29.3 164 4 18 44.4
HHH 109.2 5.7 13.3 22.6 126 9 47 51.4
Mean ±SD 97.2 ± 22.6 3.2 ± 2.8 9.7 ± 6.4 18.4 ± 9.7 111.1 ± 70.9 7.8 ± 6.0 47.5 ± 46.0 53.4 ± 34.5
>150 ng/mg
I 364.6 0.8 12.7 12.7 107 13 87 126.9
M 155.1 1.4 6.0 7.3 69 5 36 52.3
O 171.7 1.6 3.6 11.0 86 3 17 43.3
P 279.1 ----3 8.2 8.2 48 ----3 ----3 ----3
Q 158.4 0.8 3.6 5.7 68 4 34 129.4
T 681.9 2.5 29.8 29.8 249 28 221 194.3
U 190.5 15.2 29.3 29.7 198 15 96 19.6
X 171.8 5.8 14.7 29.6 127 10 36 23.2
Z 248.5 4.9 6.3 29.7 125 3 5 11.0
II 425.2 ----3 11.0 11.0 7 ----3 ----3 ----3
KK 315.3 ----3 11.0 11.0 6 ----3 ----3 ----3
PP 155.7 1.2 6.7 6.7 72 6 57 77.4
SS 181.3 3.0 8.8 28.5 123 6 24 53.2
UU 333.5 5.6 18.9 20.8 125 14 76 158.2
VV 176.8 3.7 27.3 27.3 122 25 99 51.0
YY 668.1 6.1 29.2 29.7 229 24 174 141.3
AAA 323.3 2.1 28.5 28.5 335 27 287 288.7
BBB 286.9 16.1 29.8 29.8 300 14 119 77.0
EEE 341.4 ----3 12.0 12.0 8 ----3 ----3 ----3
GGG 1165.9 ----3 11.0 11.0 7 ----3 ----3 ----3
Mean ±SD 339.8 ± 247.3 4.7 ± 4.8 15.4 ± 9.8 19.0 ± 9.9 120.6 ± 96.9 13.1 ± 9.0 91.2 ± 80.7 96.4± 76.7
1

No urine specimens screened positive at 50 ng/mL

2

No urine specimens between first negative and last positive

3

No urine specimens screened negative at 50 ng/mL